Biotech vet Gould lands $55M start­up round for a new Third Rock plat­form biotech

Af­ter leav­ing the helm of Epizyme last fall, Robert Gould took some time off, then took some more time to look over some biotech star­tups in the Third Rock pipeline. Tak­ing them out for a spin, so to speak.

Then he got a close­up of Ful­crum Ther­a­peu­tics, a new mod­el plat­form com­pa­ny tak­ing shape on Third Rock’s back­yard in Cam­bridge, MA, look­ing to use small mol­e­cules to reg­u­late genes, turn­ing them on and off in pur­suit of con­trol­ling a dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER